Companion Animal Vaccines Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Product, By Route Of Administration, By Distribution Channel, By Product, By Region, And Segment Forecasts, 2025 - 2030

Companion Animal Vaccines Market Trends

The global companion animal vaccines market size was estimated at USD 3.95 billion in 2024 and is anticipated to grow at a CAGR of 8.25% from 2025 to 2030. The market is driven by increasing pet ownership, rising awareness about pet health, and the growing prevalence of infectious diseases. For example, the increasing adoption of dogs and cats as family members has led to higher demand for preventive healthcare, including vaccinations against diseases such as rabies, distemper, and feline leukemia. Government initiatives promoting pet immunization, such as mandatory rabies vaccination programs in the U.S. and Europe, further fuel market growth. For instance, ​in 2024, the U.S. Centers for Disease Control and Prevention (CDC) implemented new regulations to prevent the reintroduction of canine rabies into the U.S. Effective August 1, 2024, these regulations require all dogs entering the U.S. to be at least six months old, appear healthy upon arrival, be microchipped with an ISO-compatible chip, and have a completed CDC Dog Import Form. Additional requirements apply to dogs from countries with a high risk of dog rabies, including valid rabies vaccination documentation.

The rising adoption of pets is a key driver, as more pet owners seek preventive healthcare to ensure the well-being of their animals. For instance, according to an article published by Pangolia Pte. Ltd., in March 2025, around 810,00 stray animals that enter shelters are returned to their owners each year. Of those animals, dogs are more likely to be returned to their owners than cats. Around 710,000 dogs are returned to their owners as opposed to 100,000 cats. When pets are returned, many owners ensure their animals receive updated vaccinations to protect against various diseases. Shelters also play a crucial role in promoting vaccinations by requiring animals to be immunized before adoption or return. With the growing trend of pet humanization, dogs, cats, and other companion animals are increasingly considered family members, leading to higher demand for routine vaccinations against diseases such as rabies, distemper, and parvovirus.

​Moreover, in recent years, the companion animal vaccine market is experiencing significant advancements driven by innovations in biotechnology and personalized veterinary care following its success in human medicine. For instance, according to an article published by Thermo Fisher Scientific Inc., mRNA technology is being applied to veterinary biologics, enabling the development of more effective and adaptable immunizations that target specific pathogens with greater precision. Moreover, advances in genomics and data analytics are facilitating personalized medicine for pets, leading to the development of targeted therapies and breed-specific vaccines. This approach ensures that vaccinations are tailored to the unique genetic makeup and health needs of individual animals, improving efficacy and reducing adverse reactions.

Furthermore, pet insurance coverage significantly drives the companion animal vaccines market by increasing pet owners' willingness and ability to invest in preventive healthcare. With insurance policies covering routine vaccinations as part of wellness plans, pet owners are more likely to keep their pets up to date on immunizations, reducing the financial burden of veterinary care. This, in turn, boosts the demand for biologics.

On Going Clinical Trials On Pet Vaccines 

Source: AVMA, Grand View Research

Market Concentration & Characteristics

The companion animal vaccines market exhibits a moderate market concentration, and the pace of the market growth is accelerating. One of the key factors fueling the market growth is notable developments in the approval and launch for dogs and cats. For instance, in August 2024, Bioveta introduced the Biocan NOVEL vaccine range against lethal canine infections to the Indian market. This versatile vaccine is suitable for dogs of all breeds and lifestyles, aiming to provide comprehensive protection and peace of mind for pet owners.

The market is witnessing a high degree of innovation, driven by advancements in biotechnology, genetic engineering, and novel vaccine delivery methods. The development of recombinant DNA vaccines, mRNA vaccines, and vector-based immunizations is enhancing both efficacy and safety compared to traditional inactivated or live-attenuated vaccines. Oral and intranasal vaccine formulations are also gaining traction, improving ease of administration and reducing stress in pets.

Within the market, there exists a moderate to high level of mergers and acquisitions activity, indicative of ongoing consolidation and strategic acquisition and partnerships among industry players. For instance, in January 2025, Ceva Sante Animale with an aim to expand into veterinary biologics and gene therapies, acquired the company, Scout Bio.

Regulations play a crucial role in shaping the companion animal vaccines market by ensuring safety, efficacy, and quality standards. Stringent regulatory frameworks, such as those established by the FDA (U.S.), EMA (Europe), and CDSCO (India), govern the approval, manufacturing, and distribution of vaccines for pets. These regulations drive innovation by encouraging research and development while also ensuring rigorous clinical trials before market entry. However, complex approval processes and compliance costs can pose challenges for smaller manufacturers, potentially limiting market competition.

Moderate regional growth in the market is driven by initiatives from key industry players. For example, in July 2024, Biogénesis Bagó inaugurated a new vaccine production facility in Campo Largo, Brazil, with a $30 million investment. This plant, now the largest veterinary vaccine producer in Latin America, is set to manufacture over 10 million doses annually for pets. The expansion strengthens Biogénesis Bagó’s foothold in Brazil’s animal health sector while broadening its influence across Latin America.

Product Insight

The attenuated live vaccines segment dominated the market and accounted for a revenue share of over 37.00% in 2024. These vaccines use weakened pathogens that stimulate a strong immune response without causing disease, making them highly effective for preventing infectious diseases in cats and dogs. Their ability to induce both humoral and cell-mediated immunity makes them a preferred choice among veterinarians and pet owners. For instance, Nobivac Canine 1-DAPPv (developed by Merck Animal Health) is a widely used attenuated live vaccine for dogs, protecting against distemper, adenovirus, parvovirus, and parainfluenza.

The recombinant vaccine segment is anticipated to grow at the fastest CAGR over the forecast period. These vaccines use genetic engineering to produce antigens that stimulate the immune system without introducing live or inactivated pathogens, reducing the risk of adverse reactions. For instance, Merial’s PUREVAX Rabies vaccine for cats utilizes recombinant canarypox technology to deliver immunity against rabies without the need for an adjuvant, significantly reducing the risk of vaccine-associated sarcomas. As advancements in biotechnology continue, recombinant vaccines are expected to dominate the market, offering improved protection against emerging and existing diseases in companion animals.

By Animal Type Insights

The canine segment dominated the market with the highest revenue share in 2024. Canines play a significant role in driving the market due to their high population, increased adoption rates, and growing healthcare awareness. Dog owners are more inclined to vaccinate their dogs against common diseases such as rabies, distemper, parvovirus, and leptospirosis, fuelling demand for canine vaccines. For instance, the rising prevalence of canine infectious diseases has led to increased vaccination campaigns and stricter pet immunization regulations. An example is Zoetis' Vanguard series, which provides broad-spectrum protection against multiple canine diseases, ensuring widespread adoption among veterinarians and dog owners.

The feline segment is expected to exhibit the fastest growth rate during the forecast period, owing to an increasing cats’ ownership. According to the American Pet Products Association, cat ownership increased among younger generations, especially the millennials. In addition, veterinary organizations and governments worldwide continue to emphasize mandatory and preventive vaccinations for cats, further driving market expansion. For instance, in March 2025, the Blue Cross Society in Pune began offering the Tri-Cat vaccine for free to protect stray and mixed-breed pet cats from major feline diseases, increasing vaccine accessibility and uptake.

By Route of Administration Insights

The subcutaneous segment dominated the market for companion animal vaccines with a revenue share of over 41.0% in 2024, due to its ease of application, reduced risk of adverse reactions, and high efficacy. This method allows vaccines to be administered under the skin, making it less invasive than intramuscular injections while ensuring efficient immune response. Veterinary professionals and pet owners prefer SC administration as it enhances compliance and minimizes pain. For example, Boehringer Ingelheim’s Purevax Rabies vaccine, specifically designed for feline use, is administered subcutaneously. It eliminates the risk of vaccine-related sarcomas, a major concern in cats, increasing its adoption rate.

The intranasal segment is expected to exhibit the fastest growth rate of 8.99% during the forecast period. Intranasal vaccines are typically administered as a single dose. The increasing prevalence of respiratory diseases in animals, coupled with rising research efforts by market players to develop improved vaccines, is expected to drive market growth. In addition, intranasal vaccines enhance mucosal immunity, providing a strong first line of defense against pathogens. This makes them particularly effective in preventing respiratory diseases in companion animals.

Distribution Channel Insight

Hospital/clinic pharmacy held the dominant share of the companion animal vaccines market in 2024. Veterinary hospitals and clinics stock a wide range of vaccines, facilitating timely administration by licensed veterinarians, which boosts demand and market growth. In addition, these facilities often participate in public health initiatives, educational campaigns, and partnerships with vaccine manufacturers to enhance pet immunization rates. For instance, in 2024, Banfield Pet Hospital, the largest general veterinary practice in the U.S., launched an updated Optimum Wellness Plan, which includes routine vaccinations for pets. This initiative has increased the adoption of vaccines for diseases like rabies, distemper, and parvovirus.

The e-commerce segment is anticipated to grow at the fastest CAGR over the forecast period. Online platforms enable direct purchasing of vaccines, reducing dependency on traditional brick-and-mortar veterinary clinics and pharmacies. This trend is fueled by rising pet ownership and the increasing preference for online shopping due to competitive pricing and doorstep delivery. Overall, e-commerce is transforming vaccine distribution by making high-quality vaccines more widely available, improving supply chain efficiency, and driving market growth globally.

Regional Insights

North America dominated the market and accounted for a revenue share of over 28% in 2024. The region is experiencing strong growth due to increasing pet ownership, rising awareness of preventive healthcare, and advancements in vaccine development. The region benefits from well-established veterinary infrastructure and a growing demand for innovative vaccines, including recombinant and oral formulations. In addition, regulatory approvals and investments by key players are fueling market expansion. For example, in 2024, FDA approved a new monoclonal antibody-based vaccine for feline infectious peritonitis (FIP), marking a significant advancement in feline healthcare. Such innovations, coupled with the convenience of e-commerce platforms and veterinary clinics promoting routine immunization, are driving market growth across North America.

U.S. Companion Animal Vaccines Market Trends

The U.S. companion animal vaccines market growth is attributed to a wide range of definitive measures adopted by the government animal care organizations consistently striving for overall improvement and growing development of cancer treatments for companion animals, such as the promising cancer vaccine for dogs, is expected to drive the demand for companion animal vaccines market significantly. As innovative therapies prove effective in extending the lives of pets diagnosed with cancer, there may be an increased demand for advanced veterinary vaccines targeting specific diseases. This trend could drive research and investment in the development of more targeted and personalized companion animal vaccines, fostering a market shift towards more advanced and effective solutions for pet health. For example, in March 2024, Yale researcher Mark Mamula developed a promising cancer vaccine for dogs, currently under USDA review.

Europe Companion Animal Vaccines Market Trends

The companion animal vaccines market in the region is anticipated to grow significantly, attributed to the rising number of pet cats and dogs, along with increased spending on pet care, is driving the demand for vaccinations. According to the 2024 FEDIAF report, 50% of European households own 166 million of the 352 million pets across Europe, reflecting a growing pet ownership trend. Regular vaccination remains crucial, as dogs and cats are susceptible to various infectious diseases such as rabies, distemper, parvovirus, and feline leukemia. To mitigate the risks of infectious and zoonotic diseases, veterinarians are increasingly advocating for preventive healthcare measures, including routine vaccinations, to ensure the well-being of pets and their owners.

The Germany companion animal vaccines market is driven by increasing pet ownership and heightened awareness of preventive healthcare. As of 2024, approximately 45% of German households own pets, with dogs and cats being the most popular companions. This rise in pet ownership has led to greater demand for veterinary services, particularly vaccinations that protect against diseases. Furthermore, public health initiatives emphasizing the importance of pet vaccinations have contributed to market growth. Educational campaigns have raised awareness about zoonotic diseases, prompting more pet owners to seek comprehensive vaccination programs for their animals.

Asia Pacific Companion Animal Vaccines Market Trends

In Asia Pacific, the market is expected to register the fastest growth rate during the forecast period, primarily driven by increasing pet ownership and heightened awareness of animal health. As more households adopt pets, particularly cats and dogs, the demand for effective vaccination programs has risen to prevent infectious diseases. Technological advancements, such as the development of DNA vaccines, have enhanced the efficacy and safety of veterinary vaccines, further propelling market expansion. Government initiatives promoting animal vaccination programs have also played a crucial role in supporting this growth.

The China market is growing at a rapid pace, due to increasing pet ownership and advancements in animal healthcare. Urbanization and changing demographics have led to a significant increase in pet ownership. Projections indicate that China's urban pet population will surpass 70 million by 2030, nearly double the number of children under the age of four. Moreover, the Chinese government's efforts to promote veterinary care, such as the 'One Health Initiative,' aim to improve animal healthcare standards, thereby boosting the market's growth potential.

Latin America Companion Animal Vaccines Market Trends

Latin American companion animal vaccines market is expected to show a growth over the forecast period. The humanization of pets has increased demand for preventive healthcare, including vaccinations. Government initiatives, such as constitutional reforms recognizing animal welfare, further support market growth. In addition, technological advancements, such as the adoption of mRNA vaccine technology, are enhancing vaccine development. These factors collectively drive the region's companion animal vaccines market.

​The Brazilian companion animal vaccines market is experiencing robust growth, driven by several key factors. One of them is the expansion of veterinary clinics and pet healthcare services across the country, further enhances accessibility to vaccinations. In addition, well-equipped veterinary facilities with advanced diagnostic capabilities enhance early disease detection, prompting timely vaccinations as part of preventive healthcare. The presence of modern veterinary hospitals also fosters collaborations with pharmaceutical companies, leading to the introduction of new and improved vaccines.

Middle East & Africa Companion Animal Vaccines Market Trends

South Africa, Saudi Arabia, UAE, and Kuwait constitute the Middle East & Africa (MEA). Companion animal vaccines market in this region is anticipated to show growth during the forecast period due to the growing trend of pet humanization, especially in urban areas, has led to higher demand for preventive healthcare, including vaccinations against several diseases. Veterinary infrastructure is expanding, with more clinics and pet healthcare facilities offering advanced vaccination programs. In addition, regulatory improvements ensure the safety and efficacy of vaccines, boosting consumer trust.

South African companion animal vaccines market is anticipated to grow at a lucrative rate, due to the increasing pet ownership and rising pet health awareness. As of April 2024, approximately 45% of South African households have pets, with 78% of these pet owners having at least one dog. This surge in pet adoption has led to greater demand for veterinary services and preventive healthcare, including vaccinations. Furthermore, the prevalence of zoonotic diseases such as rabies has underscored the necessity for effective vaccination programs.

Key Companion Animal Vaccines Company Insights

The market is fairly competitive and marked by the presence of various small and large animal vaccine manufacturers. Key factors influencing competition include the swift adoption of veterinary preventive injections and government-supported bulk procurement of veterinary vaccines. In addition, to maintain market share and expand their product portfolios, leading companies increasingly pursue strategies such as mergers and acquisitions, partnerships, and the launch of new products.

Recent Developments

• In July 2024, Biogénesis Bagó opened a new vaccine production plant in Campo Largo, Brazil, with a $30 million investment, making it the largest veterinary vaccine producer in Latin America. The facility will produce over 10 million doses annually for pets and livestock, strengthening Biogénesis Bagó's presence in Brazil’s animal health market and expanding its reach across Latin America. 

• In January 2022, Boehringer Ingelheim collaborated with MabGenesis, a biopharmaceutical company, to discover novel monoclonal antibodies in canines.

• In November 2021, Ceva created a new cryogenic storage facility in Monor by investing in its European vaccine production capacity to meet the rapidly growing demand for vaccines.

Companion Animal Vaccines Market Report Scope

Global Companion Animal Vaccines Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the companion animal vaccines market report based on animal type, product, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Attenuated Live Vaccines

  • Inactivated Vaccines

  • Subunit Vaccines

  • DNA Vaccines

  • Recombinant Vaccines

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Subcutaneous

  • Intramuscular

  • Intranasal

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Canine

  • Feline

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail

  • E-Commerce

  • Hospital/ Clinic Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America 

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of Europe

  • Asia Pacific

    • Japan

    • India

    • China

    • South Korea

    • Australia

    • Thailand

    • Rest of APAC

  • Latin America

    • Brazil

    • Argentina

    • Rest of LATAM

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA